No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

Background The use of pharmacogenomics data is increasing in clinical practice. However, it is unknown if pharmacogenomics data can be used more broadly to predict outcomes like hospitalization or emergency department (ED) visit. We aim to determine the association between selected pharmacogenomics phenotypes and hospital utilization outcomes (hospitalization and ED visits). Methods This cohort study utilized 10,078 patients from the Mayo Clinic Biobank in the RIGHT protocol with sequence and interpreted phenotypes for 10 selected pharmacogenes including CYP2D6, CYP2C9, CYP2C19, CYP3A5, HLA B 5701, HLA B 5702, HLA B 5801, TPMT, SLCO1B1, and DPYD. The primary outcome was hospitalization with ED visits as a secondary outcome. We used Cox proportional hazards model to test the association between each pharmacogenomics phenotype and the risk of the outcomes. Results During the follow-up period (median [in years] = 7.3), 13% (n=1354) and 8% (n=813) of the subjects experienced hospitalization and ED visits, respectively. Compared to subjects who did not experience hospitalization, hospitalized patients were older (median age [in years]: 67 vs 65), poorer self-rated health (15% vs 4.7% for fair/poor), and higher disease burden (median number of chronic conditions: 7 vs 4) at baseline. There was no association of hospitalization with any of the pharmacogenomics phenotypes. The pharmacogenomics phenotypes were not associated with disease burden, a well-established risk factor for hospital utilization outcomes. Similar findings were observed for patients with ED visits during the follow-up period. Conclusion We found no association of 10 well-established pharmacogenomics phenotypes with either hospitalization or ED visits in this relatively large biobank population and outside the context of specific drug use related to these genes. Traditional risk factors for hospitalization like age and self-rated health were much more likely to predict hospitalization and/or ED visits than this pharmacogenomics information.

[1]  M. Hahn,et al.  Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times , 2020, Pharmacopsychiatry.

[2]  M. Whirl‐Carrillo,et al.  PharmVar GeneFocus: CYP2D6 , 2019, Clinical pharmacology and therapeutics.

[3]  P. Austin,et al.  Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. , 2019, European heart journal.

[4]  Lisa Bastarache,et al.  Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation , 2019, JMIR Medical Informatics.

[5]  J. Cerhan,et al.  Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile , 2019, BMJ Open.

[6]  Joseph A. Sutton,et al.  Integrating pharmacogenomics into the electronic health record by implementing genomic indicators , 2019, J. Am. Medical Informatics Assoc..

[7]  Michael J. Mader,et al.  Recommendations on the Use of Ultrasound Guidance for Central and Peripheral Vascular Access in Adults: A Position Statement of the Society of Hospital Medicine. , 2019, Journal of hospital medicine.

[8]  Carolyn R Rohrer Vitek,et al.  Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). , 2019, International journal of epidemiology.

[9]  G. Hempel,et al.  Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes , 2019, Clinical Pharmacokinetics.

[10]  Peggy L. Peissig,et al.  Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center , 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  N. Shah,et al.  Care Transitions Program for High-Risk Frail Older Adults is Most Beneficial for Patients with Cognitive Impairment. , 2019, Journal of Hospital Medicine.

[12]  S. Scherer,et al.  Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19 , 2019, Drug Metabolism and Disposition.

[13]  Pedro J. Caraballo,et al.  Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network , 2019, J. Am. Medical Informatics Assoc..

[14]  J. Hanlon,et al.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults , 2019, Journal of the American Geriatrics Society.

[15]  Joshua C. Denny,et al.  Developing and Evaluating Mappings of ICD-10 and ICD-10-CM Codes to Phecodes , 2018, bioRxiv.

[16]  G. Imbens,et al.  Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity‐score matched study , 2018, Depression and anxiety.

[17]  V. Napolioni,et al.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort , 2018, Pharmacogenomics and personalized medicine.

[18]  Scott M. Brue,et al.  Data Resource Profile: Expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP). , 2018, International journal of epidemiology.

[19]  Richard M Weinshilboum,et al.  Pharmacogenomics: Precision Medicine and Drug Response , 2017, Mayo Clinic proceedings.

[20]  N. Cox,et al.  Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record , 2017, PloS one.

[21]  J. Cerhan,et al.  Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6 , 2017, Pharmacogenomics and personalized medicine.

[22]  Richard Schulz,et al.  Families Caring for an Aging America , 2016 .

[23]  M. Ingelman-Sundberg,et al.  International Journal of Molecular Sciences the Importance of Patient-specific Factors for Hepatic Drug Response and Toxicity , 2022 .

[24]  Darshak M Sanghavi,et al.  Patterns of care for clinically distinct segments of high cost Medicare beneficiaries. , 2016, Healthcare.

[25]  M. Whirl‐Carrillo,et al.  Prediction of CYP2D6 phenotype from genotype across world populations , 2016, Genetics in Medicine.

[26]  Yuan Ji,et al.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. , 2016, The Journal of molecular diagnostics : JMD.

[27]  J. Cerhan,et al.  A novel housing-based socioeconomic measure predicts hospitalisation and multiple chronic conditions in a community population , 2015, Journal of Epidemiology & Community Health.

[28]  J. Cerhan,et al.  Health behaviors and quality of life predictors for risk of hospitalization in an electronic health record-linked biobank , 2015, International journal of general medicine.

[29]  P. Hu,et al.  Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems , 2015, European Journal of Clinical Pharmacology.

[30]  T. Therneau,et al.  Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. , 2014, Mayo Clinic proceedings.

[31]  M. Tinetti,et al.  IOM and DHHS Meeting on Making Clinical Practice Guidelines Appropriate for Patients with Multiple Chronic Conditions , 2014, The Annals of Family Medicine.

[32]  Robert J. Stroebel,et al.  Risk-stratification methods for identifying patients for care coordination. , 2013, The American journal of managed care.

[33]  Jyotishman Pathak,et al.  Hospitalizations and emergency department use in Mayo Clinic Biobank participants within the employee and community health medical home. , 2013, Mayo Clinic proceedings.

[34]  M. Porter,et al.  Redesigning primary care: a strategic vision to improve value by organizing around patients' needs. , 2013, Health affairs.

[35]  Ethan A. Halm,et al.  Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review , 2013, Journal of General Internal Medicine.

[36]  B. Yawn,et al.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. , 2012, Mayo Clinic proceedings.

[37]  G. Maurer,et al.  Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study , 2012, Journal of thrombosis and haemostasis : JTH.

[38]  B. Yawn,et al.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. , 2012, Mayo Clinic proceedings.

[39]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[40]  A. Crosby,et al.  Emergency department visits for overdoses of acetaminophen-containing products. , 2011, American journal of preventive medicine.

[41]  M. Porter,et al.  What is value in health care? , 2010, The New England journal of medicine.

[42]  Rajeev Chaudhry,et al.  Use of an electronic administrative database to identify older community dwelling adults at high-risk for hospitalization or emergency department visits: The elders risk assessment index , 2010, BMC health services research.

[43]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[44]  Rui Qin,et al.  The influence of neighborhood environment on the incidence of childhood asthma: a propensity score approach. , 2010, The Journal of allergy and clinical immunology.

[45]  J Lyle Bootman,et al.  Value in health care. , 2006, Managed care interface.

[46]  Emmett Keeler,et al.  Development of a Method to Identify Seniors at High Risk for High Hospital Utilization , 2002, Medical care.

[47]  H. Perry,et al.  Polypharmacy and hospitalization among older home care patients. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[48]  P Shelton,et al.  The community assessment risk screen (CARS): identifying elderly persons at risk for hospitalization or emergency department visit. , 2000, The American journal of managed care.

[49]  Chad Boult,et al.  Screening Elders for Risk of Hospital Admission , 1993, Journal of the American Geriatrics Society.

[50]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[51]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[52]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.